DailyStocks Stock Article Search

https://seekingalpha.com/article/4709563-regenxbio-inc-rgnx-q2-2024-earnings-call-transcript?source=feed_sector_transcripts Aug 01, 2024 - REGENXBIO Inc. (NASDAQ:NASDAQ:RGNX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ETCompany ParticipantsPatrick Christmas - CLOCurran Simpson -... 0

https://www.zacks.com/stock/news/2314680/regenxbio-rgnx-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2314680 Aug 01, 2024 - Regenxbio (RGNX) delivered earnings and revenue surprises of 18.60% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2291689/fda-expands-sarepta-s-srpt-dmd-gene-therapy-label?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2291689 Jun 21, 2024 - Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status. 0

https://www.fool.com/investing/2024/03/13/does-this-1-new-threat-make-sarepta-therapeutics/?source=iedfolrf0000001 Mar 13, 2024 - The threat is still emerging, but it could be significant. 0

https://www.zacks.com/stock/news/2236810/regenxbio-rgnx-soars-15-on-interim-data-from-dmd-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236810 Mar 06, 2024 - Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement. 0

https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector. 0